MVD1

MVD1 is an oral small-molecule nitroalkene derivative of salicylate, chemically identified as 5-(2-nitroethenyl)salicylic acid, being developed by Eolo Pharma as a first-in-class activator of creatine-dependent energy expenditure for the treatment of obesity and obesity-related metabolic dysfunctions, including insulin resistance, hypertriglyceridemia, and non-alcoholic fatty liver disease. Preclinical studies show that MVD1 enhances mitochondrial respiration and stimulates creatine-driven, non-shivering thermogenesis in both white and brown adipose tissue, leading to weight loss and improvements in glucose tolerance and liver steatosis at doses far lower than salicylate, while its anti-inflammatory AMPK- and NF-κB–related effects appear insufficient to explain the full metabolic profile.[1][4] Mechanistically, MVD1 covalently modifies thiol residues and binds mitochondrial creatine kinases CKMT1/2, increasing creatine cycling and thermogenesis independently of uncoupling protein 1 and with minimal effects on food intake, and in a phase 1A/B randomized, double-blind, placebo-controlled trial it demonstrated a favorable safety and tolerability profile with early signals of weight loss and improved insulin resistance in overweight or obese volunteers.[1][2][3][4]

Other names

salicylate nitroalkene derivative